AREG and head and neck carcinoma: In various cancer types, including Head and neck carcinomas, Amphiregulin (AREG) overexpression has been involved in therapeutic failure and resistance to anti-EGFR therapies [32, 47] or to vincristine, a microtubule-destabilising agent [34].